Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Theradiag    ALTER   FR0004197747

THERADIAG

(ALTER)
  Report  
Delayed Quote. Delayed Euronext Alternext - 10/21 09:58:14 am
0.992 EUR   +0.81%
09/2424 / 09 / 2019 : Theradiag announces improved results for H1 2019
PU
09/24THERADIAG : Announces Improved Results for H1 2019
BU
07/1818 / 07 / 2019 : Theradiag announces first-half revenue up 9%
PU
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Theradiag : enhances its oncology offer, with an 8th test in its Lisa-Tracker theranostic range: Avastin® test received CE marking (08 / 07 / 2014 )

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/21/2014 | 10:56am EDT
THERADIAG enhances its oncology offer, with an 8th test in its Lisa-Tracker theranostic range: Avastin® test received CE marking

Croissy-Beaubourg and Montpellier, 8 July 2014 - THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing in in-vitro diagnostics and theranostics, today announces that its Lisa-Tracker range has been further expanded, with an 8th test receiving CE marking in oncology.
With the monitoring of the drug and of the anti-drug antibodies, this new test could optimize the treatment of patients on Avastin® (bevacizumab molecule). Avastin® is the only anti-angiogenic 1 therapy available for treating patients with advanced breast, colon, lung, kidney or ovarian cancer, which are responsible for more than 2.5 million deaths every year.
This kit, developed by Theradiag, is the Lisa-Tracker range's second test in oncology and will soon be marketed worldwide. It meets a major need from practitioners, with more than a million patients currently being treated with Avastin®. In 2013, sales of this drug totaled approximately 6.7 billion dollars (+8% compared with 2012). Furthermore, a vast program of more than 500 clinical trials is also currently underway and is looking into the possible use of Avastin® in around fifty additional types of tumor.

Michel Finance, CEO of THERADIAG, comments: "This 8th CE marked test is further proof of our commitment and our expertise in the development of the Lisa-Tracker range and our activity in theranostics. It enables us to expand our range and our activity to oncology. Further developments are ongoing, and will result in additional CE markings in 2014."

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of HIV/AIDS and rectal cancer. Theradiag is thus participating in the development of "customized treatment", which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-
Vallée, near Paris, and in Montpellier, and has over 60 employees.

1 Anti-angiogenic treatment: the use of drugs to inhibit angiogenesis, i.e. the production of blood vessels that irrigate cancerous tumors. The tumors, thus starved of blood, gradually disappear.

1/2

Theradiag

Investor Relations

Nathalie Trepo

Phone: +33 1 64 62 10 12

ntrepo@theradiag.com

NewCap.

Financial communications/

investor relations Valentine Brouchot / Pierre Laurent

Phone: +33 1 44 71 94 94 theradiag@newcap.fr

Alize RP

Press

Caroline Carmagnol theradiag@alizerp.com Phone: +33 6 64 18 99 59

2/2

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on THERADIAG
09/2424 / 09 / 2019 : Theradiag announces improved results for H1 2019
PU
09/24THERADIAG : Announces Improved Results for H1 2019
BU
07/1818 / 07 / 2019 : Theradiag announces first-half revenue up 9%
PU
07/18THERADIAG : Announces First-half Revenue Up 9%
BU
07/18THERADIAG : 2nd quarter earnings
CO
06/03THERADIAG : Voting Results of Theradiag's Annual Ordinary and Extraordinary Gene..
BU
05/16THERADIAG : Press Release
CO
05/14THERADIAG : Strengthens Its Presence in the United States on Biotherapy Monitori..
BU
04/0404 / 04 / 2019 : Theradiag and HOB Biotech settle their legal dispute
PU
04/04THERADIAG : and HOB Biotech Settle Their Legal Dispute
BU
More news
Financials (EUR)
Sales 2019 9,20 M
EBIT 2019 -0,70 M
Net income 2019 -0,30 M
Finance 2019 3,50 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 -
EV / Sales2019 0,54x
EV / Sales2020 0,46x
Capitalization 8,50 M
Chart THERADIAG
Duration : Period :
Theradiag Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERADIAG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 1,85  €
Last Close Price 0,99  €
Spread / Highest target 86,5%
Spread / Average Target 86,5%
Spread / Lowest Target 86,5%
EPS Revisions
Managers
NameTitle
Bertrand Michel Marle de Castelnau Chief Executive Officer
Pierre Armand Morgon Chairman
Ermis Parussini Director-Operations, Research & Development
Fabienne François Chief Financial & Administrative Officer
Vincent Fert Director
Sector and Competitors
1st jan.Capitalization (M$)
THERADIAG3.58%9
GUARDANT HEALTH, INC.73.64%6 068
GENSCRIPT BIOTECH CORPORATION56.19%3 853
IOVANCE BIOTHERAPEUTICS, INC.121.13%2 423
INVITAE CORPORATION57.41%1 657
MIRACA HOLDINGS INC.4.40%1 323